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A model has been constructed using computer graphics for human renin based on the sequence derived 
from that of the gene and the 3-dimensional structure defined at high resolution for other homologous 
aspartic proteinases. Human renin can adopt a 3-dimensional structure close to that of other aspartic 
proteinases, in which amino acids corresponding to intron-exon junctions in the gene are at surface regions 
in the 3-dimensional structure. As expected, the essential catalytic residues are retained and the nearby 
residue 304 is alanine as in the mouse sequence, supporting the idea that Asp 304 of other aspartic 
proteinases may contribute to the low pH of their optimal activity. There are interesting differences at 
subsite S; which may contribute to the specificity of human renin. Certain residues at the surface of the 
enzyme adjacent to the active site cleft are unique to renins and may play a role in recognition and binding 
of angiotensinogen. 
Human renin Computer graphics model 
1. INTRODUCTION 
The aspartic proteinase, renin, catalyses the 
first, and rate-limiting step, in the conversion of 
angiotensinogen to angiotensin II. As the latter is 
important in the regulation of blood pressure, the 
design of renin inhibitors is of great phar- 
macological interest. Some progress has been made 
by modification of angiotensinogen sequences [l] 
especially by the introduction of modified amino 
acids such as statine residues [2] and reduced pep- 
tide bonds [3]. However, a more rational approach 
would be based on a knowledge of the 
enzyme-substrate transition state complex. 
The first steps in this direction were the deter- 
mination of the amino acid [4] and cDNA [5] se- 
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quences of mouse submaxillary renin. The high 
homology of these sequences with those of other 
aspartic proteinases indicated that the enzymes 
might have similar 3-dimensional structures, and 
enabled models to be constructed using computer 
graphics [6,7]. The catalytic residues (Asp 32 and 
Asp 215, pepsin numbering) lie in the centre of a 
deep and extended cleft, which can accommodate 
7 or 8 amino acids [6]. However, residue 304, 
which in other aspartic proteinases is invariant as 
aspartate, was uniquely alanine in mouse submax- 
illary renin; this may contribute to the higher pH 
optimum for catalytic activity. In most aspartic 
proteinases, subsite S; , residue 189 is usually 
phenylalanine or tyrosine, but in mouse submax- 
illary renin it is a much smaller serine, complemen- 
ting the tyrosine in angiotensinogen. The predicted 
3-dimensional structure of mouse submaxillary 
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renin has been used as a basis for modelling renin 
substrate interactions [8]. Mouse kidney renin, 
which is a separate gene product [9,10], resembles 
mouse submaxillary renin in specificity, catalytic 
activity, and sequence (C. Burt and W.J. Bram- 
mar, unpublished) [ 111. 
A detailed understanding of the specificity of the 
human enzyme depends on knowledge of the 
amino acid sequence and this has now become 
available from the genomic DNA sequence [12] 
and from two cDNA sequences [ 13,141. Here, we 
describe a model constructed using interactive 
computer graphics for human renin based on the 
sequence derived from that of the gene [12]. We 
show that human renin can adopt a 3-dimensional 
structure close to that of the other aspartic pro- 
teinases in which amino acids corresponding to 
intron-exon junctions in the gene are at surface 
regions in the 3-dimensional structure. We hiscuss 
the specificity subsites and various residues on the 
surface of the enzyme adjacent to the active site 
cleft which might play a role in recognition and 
binding of angiotensinogen. We believe that the 
model provides a useful guide to the rational 
design of inhibitors of human renin which may be 
of value in the treatment of hypertension. 
2. MATERIALS AND METHODS 
The sequence of human renin determined in [ 121 
was aligned with that of mouse submaxillary renin 
and other aspartic proteinases in a 3-stage interac- 
tive process. First, the sequences of mouse sub- 
maxillary and human renins were aligned together 
as in [14]. Second, the renin sequences were align- 
ed with those of other aspartic proteinases in- 
cluding porcine pepsin [ 151, human pepsin [ 161, 
chicken pepsin [17], calf chymosin [18], en- 
dothiapepsin (V. Pedersen and L. Pearl, un- 
published) and penicillopepsin [19]. Table 1 in- 
dicates residues which are conserved (i) in all 
aspartic proteinases, (ii) only in mammalian en- 
zymes and (iii) in all aspartic proteinases except he 
renins. The sequence of human renin has been 
numbered using the sequence of porcine pepsin 
with insertions indicated by alphabetical 
postscripts. 
The third stage of the alignment depended on 
reference to the known structures of other aspartic 
proteinases defined by X-ray analysis. These in- 
elude a medium-resolution unrefined model of 
porcine pepsin [20] and high-resolution structures 
of rhizopuspepsin [21], penicillopepsin [22] and 
endothiapepsin [23]. As only the a-carbon coor- 
dinates were available for porcine pepsin, and no 
sequence has been determined for rhizopuspepsin, 
we did not use these structures extensively. In the 
third stage of the alignment we attempted to retain 
the hydrophobic residues of the core of these en- 
zymes as non-polar and to limit insertions and 
deletions to surface regions and loops. The align- 
ment is indicated in table 1 by the pepsin number- 
ing system. 
The 3-dimensional structure of human renin was 
then modelled using FRODO [24] modified by Dr 
I.J. Tickle and Dr T.A. Jones for an Evans and 
Sutherland Picture System 2. We used the 
3-dimensional atomic coordinate set of en- 
dothiapepsin 1231 refined to an agreement (R) 
value of 0.16 at 2.1 A resolution as a basis for the 
model construction. Firstly, the alignment of se- 
quences was used to identify the residues which are 
identical in endothiapepsin and human renin. 
Secondly, other residues of the hydrophobic core 
were replaced in the model by those of human 
renin. The positions of their side chains were ad- 
justed interactively so that they occupied a position 
as close as possible to that of the side chains of en- 
dothiapepsin while adopting acceptable torsion 
angles and interatomic distances with non-bonded 
atoms. Thirdly, insertions and deletions were made 
using FRODO. In most cases this involved exten- 
ding or shortening hairpin loops by one or two 
amino acid residues: the main chain parameters 
were guided by analyses of other &bend confor- 
mations (B.L. Sibanda and J.M. Thornton, un- 
published) and by comparison with other aspartic 
proteinases as suggested in [25]. Finally, all surface 
side chains were added in positions which approx- 
imated those of endothiapepsin. Ion pair interac- 
tions and hydrogen bonds were optimised, torsion 
angles given preferred values, and disallowed in- 
teratomic contacts avoided. We experimented with 
the use of energy-minimization programs to op- 
timise the interatomic interactions using the poten- 
tial functions developed in [26], in which hydrogen 
atoms were explicitly considered for all residues in 
the active site region. However, these led to unac- 
ceptable movements of the water molecules in the 
active site. 
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Table 1 
Human renin 
- deletions compared to porcine pepsin 
m Conserved in all mammalian aspartic proteinases. 
0 Conserved in all mammalian aspartic proteinases and in endothiapepsrn. 
I! Hydrophobic core. 
X" Unique to all renins; conserved in all other aspartic protelnases. 
jl Identical in human renin and endothlapepsln, but different in pepsin. 
x+ Varied only In human renin. 
$ , presumptive 0-glycosylation sites. 1, positions of intron-exon junctions. The numbering system is derived from that 
of porcine pepsin and indicates the alignment of the sequences. The sequence within parentheses is not found in the 
gene sequence of [ 121, but is in both cDNA sequences [ 13,141 
The model of human renin was used as the basis 
for a substrate docking experiment. The residues 
P4-Pi were placed by analogy with the inhibitors 
bound to rhizopuspepsin [27] and penicillopepsin 
[28]. This brought the scissile bond into close jux- 
taposition with a water molecule bound to the two 
active site aspartates [29]. The water was assumed 
to participate in a tetrahedral intermediate at the 
peptide carbonyl. The substrate residues (Pi’-P;) 
were then fitted into the specificity pockets in the 
remaining half of the cleft. The subsite, Si, was 
assumed to comprise residues in the region of 213 
and 301 while subsite S; must be close to 189 
[30,31]. 
3. RESULTS AND DISCUSSION 
Fig.1 shows orthogonal stereo views of the 
model of human renin. 
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The alignment of the human renin sequence with 
that of the other aspartic proteinases was achieved 
in most places without ambiguity owing to the very 
few insertions and deletions that have occurred 
between the enzymes of fungal and mammalian 
origins. When compared to the alignment used in 
modelling the mouse submaxillary renin [6] there is 
only one difference. This occurs in residues 
157- 188 (pepsin numbering) where the existence of 
two similar renin sequences (mouse submaxillary 
and human) implied that Gly 168, Asp 171 and Tyr 
175 should be invariant in these as well as other 
aspartic proteinases. This necessitated two inser- 
tions at the P-bend between strands 147-156 and 
162-171. However, in the region of residues 
103-117 where the homology between different 
aspartic proteinases is low, there is still a real am- 
biguity in alignment. We have chosen to make the 
alignment: 
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a 
b 
Fig. 1. Stereo view of the 3-dimensional model of human renin viewed (a) along the active site cleft and (b) perpendicular 
to the cleft. 
Human renin 
Human pepsin 
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This introduces an insertion and deletion, but con- 
serves residue 111 as phenylalanine, a residue 
which contributes to the core and which is conserv- 
ed in all the pepsins. Nevertheless the following 
alignment is equally plausible: 
Human renin 
Human pepsin 
This presents some difficulties, particularly in the 
placement of polar and non-polar residues at 
equivalent positions. The ambiguity cannot be 
resolved at present and in any case the great dif- 
ferences in sequences in this region may indicate 
different conformations which must be defined by 
a detailed X-ray analysis of the human renin. 
In general, the model building gives convincing 
evidence that there is a close 3-dimensional 
resemblance between renin and other aspartic pro- 
! 9 10 11 12 13 14 
ALPFML 
GSFLYY 
rs 
A 
A - 
16 17 18 
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teinases. Most of the 92 residues which make 
substantial contributions towards the core of the 
aspartic proteinase fold are conserved as 
hydrophobic. Where large residues are replacing 
smaller ones there are compensatory changes in 
positions which are contiguous in the tertiary 
structure so that the core occupies the same 
volume. Most hydrophobic core residues which are 
conserved in all other aspartic proteinases are con- 
served in renins; these include Tyr 14, Phe 31, Trp 
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Fig.2. (a) The residues which comprise the inner surface of the active site cleft of human renin and (b) a similar view 
with an angiotensinogen sequence bound. 
39, Val40, Va191, Phe 151, Trp 190, Tyr 275, Phe 
306 and Phe 314. The exception, Val89, is conser- 
vatively varied to isoleucine in renin. Several polar 
residues are hydrogen bonded into the core and 
conserved in all aspartic proteinases; these include 
serine 42 as well as Thr 33 and Thr 216 which are 
hydrogen bonded together in the active site region 
~291. 
Asp 11 is conserved as an acid group in human 
renin as it is in all other aspartic proteinases with 
the exception of mouse submaxillary renin; this ap- 
pears to form internal hydrogen bonds. Asp 87, 
Asp 118, Asp 171 and Asp 315 are also conserved 
in all aspartic proteinases for reasons which are 
probably structural. However, Asp 304 of pepsin 
and all other aspartic proteinases is alanine in 
human as well as mouse submaxillary renin. We 
have suggested that this is necessary for raising the 
pH optimum of mouse submaxillary renin to a 
106 
more neutral pH compared to other aspartic pro- 
teinases as this residue is in a mainly hydrophobic 
environment and close to the active site. Its ex- 
istence as alanine in the human renin supports this 
contention. 
The conformation of the main chain of renin 
can be close to that of other aspartic proteinases in 
most parts. This is made possible by the conserva- 
tion of glycines at positions 21, 34, 78, 82, 119, 
122, 168, 217 and 322 in all aspartic proteinases. 
The high proportion of glycines amongst the in- 
variant residues is expected as they uniquely have 
no side chain; they may adopt unusual torsion 
angles and pack in ways unavailable to other 
amino acid residues. It is of interest that Gly 76 is 
invariant in all other aspartic proteinases; the ex- 
istence of Ser 76 in human renin is likely to change 
the conformation at this P-hairpin which is close to 
the active site (vide infra). 
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The cystine disulphide bridge, Cys 250-Cys 283, 
is conserved in renins as in all other aspartic pro- 
teinases. This plays a role in holding the residues in 
the sequence between the half-cystines into the 
3-dimensional structure. The disulphide bridges 
Cys 45-Cys 50 and Cys 206-Cys 210 are accom- 
modated with little change of conformation. 
For modelling human renin endothiapepsin of- 
fers several advantages compared to other struc- 
tures defined at high resolution. For example, the 
deletions at residues 10, 25, 26, 64, 207 and 208 of 
penicillopepsin are not found in endothiapepsin. 
An insertion of two extra residues in endothiapep- 
sin in the,&-bend between 278 and 283 compared to 
pepsin occurs at a position where residues are also 
inserted in human and mouse renins. At most posi- 
tions where there are insertions in human renin 
when compared to endothiapepsin, the changes are 
unique to renins. These include two residues uni- 
quely inserted in a surface loop (46a, 46b) and the 
insertions of residues at 159 and 279-282 which in- 
volve simple extensions of the P-hairpins. The ex- 
istence of the proline-rich sequence PPPTGP 
(293-298), which prevents a pepsin-like conforma- 
tion, is a further characteristic structural feature of 
renins .
In summary, human renin, like mouse submax- 
illary renin [6], may adopt a 3-dimensional struc- 
ture closely similar to that of other aspartic pro- 
teinases. The differences are mainly confined to 
changes of side chains, which do not affect the 
main chain fold. Where insertions or deletions oc- 
cur they are accommodated at the surface. We 
must now consider the implication of the model 
constructed using computer graphics for the 
biology of human renin. 
In the active site of aspartic proteinases, Asp 32 
and Asp 215 are hydrogen bonded together 
through their carboxyl groups which are coplanar 
and symmetrically arranged [22,29]: these are con- 
served in renins. The symmetrical arrangement is 
extended by the conservation of topologically 
equivalent threonines at 33 and 216 which 
hydrogen bond the two strands of polypeptide 
together, and glycines 34 and 217 which allow the 
chain to fold sharply so that 34 NH and 217 NH 
are close to the carboxylates 061 of Asp 32 and 
Asp 215, respectively. All of these residues are con- 
served in both human and mouse renins. However, 
in previously sequenced aspartic proteinases, in- 
eluding mouse submaxillary renin, the arrange- 
ment is completed by serines or threonines at 35 
and 218 which hydrogen bond through their side 
chain hydroxyl groups to the carboxylate OS2 of 
Asp 32 and Asp 215, respectively. In human renin 
residue 35 is serine, but residue 218 is uniquely 
alanine. This introduces a slight asymmetry and 
may contribute to a small change of the properties 
of the catalytic residues. It cannot, however, be 
responsible for the major differences of pH op- 
timum between renin and other aspartic pro- 
teinases as this sequence difference is not shared by 
mouse submaxillary renin [4,26] or mouse kidney 
renin (C. Burt and W.J. Brammar, unpublished) 
1111. 
Although the catalytically essential Asp 32 and 
Asp 215 and most of the amino acids close to them 
are identical in human and other aspartic pro- 
teinases, there are differences in the residues which 
line the active site cleft and define the substrate 
specificity. Table 2 lists the residues which define 
Table 2 
Possible specificity subsites in human renin 
Residues close to 
substrate (~4.5 A) 
Residues in proximity 
of substrate (>4.5 A) 
s4 
s3 
s2 
SI 
Si 
Si 
S< 
Tyr 220 
Thr 12, Gln 13, 
Phe 111 
Thr 77, Ser 76, 
Ala 218 
Tyr 75, Thr 77, 
Val 120, Val 30, 
Phe 111, Asp 32 
Leu 213, Asp 215 
Ser 35, Leu 73, 
Gin 128, Arg 74 
Thr 187, Val 189, 
Gln 191, Leu 213, 
Glu 127 
Thr 284, Met 10, 
Asp 245, Ser 219, 
Tyr 275 
Ser 219, Pro 110, 
Ala 114 
His 288, Tyr 220 
Trp 39 
Ala 301, Ser 222, 
Thr 216, Thr 299, 
Val 189 
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the subsites S&j. The locations of these subsites 
are deduced from studies with other aspartic pro- 
teinases. Modelling of a substrate into en- 
dothiapepsin showed that the cleft accommodated 
7 or 8 residues and pockets were identified for the 
subsites Si and S1’ on either side of the scissile bond 
[30,3 11. 
The positions of the other subsites are in the 
cleft, but involve less well defined pockets. The 
assignments for Sd-Si were refined and largely 
confirmed by direct X-ray studies of inhibitors 
bound to penicillopepsin [28] and to rhizopuspep- 
sin [27]. There are no direct studies which une- 
quivocally define S{-S;, but the original 
assignments have been improved by more precise 
modelling using the refined coordinates of en- 
dothiapepsin. It is interesting that the subsites are 
in similar positions in the NH2- and COOH- 
terminal lobes of the aspartic proteinases 
[29,32,33]. 
In human renin subsite Si is a large hydrophobic 
pocket surrounded by Tyr 75, Thr 77, Val 120, Val 
30 and Phe 111. This pocket is certainly not 
smaller than that in human pepsin as might be ex- 
pected from the preference for leucine in angioten- 
sin. Indeed, it is remarkably conserved with the ex- 
ception of a valine at 120 instead of the leucine or 
isoleucine found in other aspartic proteinases. 
Subsite Sl is also large, involving Leu 213, Ala 
301, Ser 222. The presence of leucine at 213, which 
replaces isoleucine in other aspartic proteinases 
and valine in mouse renin, is the only factor which 
could account for specificity for a smaller side 
chain at Pi of different shape. 
Most residues in the subsites SZ, S3 and Sq are 
identical or very similar in mouse and human 
renins although they differ from those of other 
mammalian aspartic proteinases [6]. Greater dif- 
ferences between renins and other aspartic pro- 
teinases are found on the COOH-terminal side of 
the scissile bond, in particular at S$ , where valine 
189 replaces erine in mouse renin and a tyrosine or 
phenylalanine in other aspartic proteinases. The 
smaller hydrophobic residue allows the substrate 
residue at Pi to be large and to attain a different 
position compared to other aspartic proteinases. 
The histidine in the human angiotensinogen se- 
quence could easily be accommodated and the 
positive charge of the imidazole may be com- 
plemented by Glu 127 which is uniquely acidic in 
human renin. 
There are many interesting differences between 
renins and other aspartic proteinases in the surface 
regions adjacent to the active site cleft. These may 
be important for two reasons. First, they may be 
involved in conformational changes on substrate 
binding and provide further interactions at P4, PZ 
and PI accounting for specificity at these posi- 
tions. Secondly, they may participate in binding 
the macromolecular angiotensinogen molecule. In 
fact, the large size of angiotensinogen (453 
residues) would imply extensive intermolecular 
surface contacts during proteolysis. 
Fig.3 shows this surface region of human renin 
which comprises polypeptide loops characteristic 
of renins. PPPTGP is also found in mouse renins 
and must provide a rather rigid structure. The ad- 
jacent loop involves the sequence Lys 240, Lys 241, 
Fig.3. The arrangement of the residues at the edge of the active site viewed in the same direction as fig.2. 
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Fig.4. The P-hairpin in human renin which may be cleaved to give a 2-chain enzyme. 
Fig.5. A stereo view of the model of human renin showing only a-carbon atoms and virtual bonds. The positions of 
intron-exon junctions are indicated by numbers on the two closest amino acid positions. 
Arg 242 which is also a highly basic region in 
mouse renins. Other basic residues occur at Arg 74 
and in the extended P-hairpin Glu (278)-Glu-Ser- 
Tyr-Ser-Ser-Lys-Lys-Leu (283). In mouse submax- 
illary renin, the chain is cleaved in this region to 
give two chains. In the mouse submaxillary enzyme 
this form has a lowered activity and changed 
specificity [34] which may result from rearrange- 
ment of the cleaved chain into the active site cleft. 
In the human enzyme the two lysines are less ac- 
cessible and proteolytic cleavage may not occur so 
easily. Human renin has two presumptive O- 
glycosylation sites, Asn-’ Thr’ Thr’ and Asn6’ 
Gly6’ Thr69 1121. These occur at surface regions 
which make them readily accessible to the glycosyl 
transferases of the endoplasmic reticulum. 
Authors in [ 121 have sequenced the human renin 
gene and so it is possible to compare this with the 
available complementary DNA sequences for 
human renin. A three residue insertion - residues 
Asp 158, Ser 159a and Glu 159b in table 1 - either 
exists as a small exon yet to be located or is 
evidence of polymorphism. As these residues lie at 
a P-bend their presence has little effect on the 
integrity of the structure. 
Comparison of the gene structure with the com- 
plementary DNA sequence confirms the existence 
of 8 introns in the gene for preprorenin, in posi- 
tions closely similar to those found in the pep- 
sinogen gene [ 161. 
We may now consider the positions of the 7 in- 
trons which occur within the coding region for 
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renin with respect to the 3-dimensional model of 
human renin. In table 1 small arrows indicate the 
positions of intron-exon junctions, and their posi- 
tions are shown in fig.5. The arrangement of the 
exons is not precisely related as would be expected 
by the gene duplication suggested in [32] although 
others [ 1 I] have suggested that the clustering of the 
exons supports this hypothesis. The junctions at 
11-12, 90-91, 158-159, 196-197 and 278-278a 
are all on P-hairpins, i.e., close to the turns bet- 
ween two hydrogen-bonded antiparallel strands of 
&sheet. They are all in surface regions accessible 
to the solvent. The intron-exon junctions at 50-51 
and 245-246 are also on the surface strands of the 
renin molecule. Most of the amino acid sequences 
encoded by nucleotides flanking a splice-site 
mRNA are highly variable. The 3-residue length 
insertion noted in human renin occurs at the splice 
junction 159. The residues inserted in region 280 of 
renin relative to other aspartic proteinases also oc- 
cur at a splice junction. Other intron-exon junc- 
tions are close to regions of high sequence 
variability, a fact which can be easily seen from 
table 1, where the conserved regions amongst 
aspartic proteinases are indicated by circles around 
the residues. Thus the members of the aspartic pro- 
teinase gene family such as pepsin and renin ap- 
pear to be excellent examples of the sliding- 
junction model of gene family evolution proposed 
in [35] for other enzymes. 
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